These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 200628)

  • 21. TgPVR21 mice for testing type-3 oral poliovirus vaccines: role of clinical observation and histological examination.
    Dragunsky E; Chernokhvostova Y; Taffs R; Chumakov K; Gardner D; Asher D; Nomura T; Hioki K; Levenbook I
    Vaccine; 1997 Dec; 15(17-18):1863-6. PubMed ID: 9413095
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potential use of new poliomyelitis vaccines: memorandum from a WHO meeting.
    Bull World Health Organ; 1990; 68(5):545-8. PubMed ID: 1963117
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Significance of a newly identified attenuating mutation in Sabin 3 oral poliovirus vaccine.
    Mento SJ; Weeks-Levy C; Tatem JM; Gorgacz EJ; Waterfield WF
    Dev Biol Stand; 1993; 78():93-9; discussion 99-100. PubMed ID: 8388835
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Ultrastructural changes in the central nervous system of monkeys in poliomyelitis].
    Erman BA; Tulakina LG
    Arkh Patol; 1976; 38(10):64-70. PubMed ID: 190980
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutations in Sabin 2 strain of poliovirus and stability of attenuation phenotype.
    Rezapkin GV; Fan L; Asher DM; Fibi MR; Dragunsky EM; Chumakov KM
    Virology; 1999 May; 258(1):152-60. PubMed ID: 10329577
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Succession of mutations in the Sabin strain of type 3 poliovirus replicating in the central nervous system of monkeys.
    Lu Z; Asher DM; Levenbook IS; Chumakov KM
    Virology; 1996 Jun; 220(2):285-9. PubMed ID: 8661379
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Live attenuated oral poliovirus vaccine: problem areas in production.
    Beale AJ
    Rev Infect Dis; 1984; 6 Suppl 2():S334. PubMed ID: 6429813
    [No Abstract]   [Full Text] [Related]  

  • 28. Neurovirulence of attenuated type 1 poliovirus vaccine strains after intramuscular inoculation of rhesus monkeys.
    KIRSCHSTEIN R; BARON S; BORMAN GS; MURRAY R; PERKINS FT; HOTTLE G
    Virology; 1960 May; 11():300-2. PubMed ID: 14409387
    [No Abstract]   [Full Text] [Related]  

  • 29. Development of candidates for new type 2 and type 3 oral poliovirus vaccines.
    Kohara M; Abe S; Yoshioka I; Nomoto A
    Dev Biol Stand; 1993; 78():141-8. PubMed ID: 8388824
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlation between amount of virus with altered nucleotide sequence and the monkey test for acceptability of oral poliovirus vaccine.
    Chumakov KM; Powers LB; Noonan KE; Roninson IB; Levenbook IS
    Proc Natl Acad Sci U S A; 1991 Jan; 88(1):199-203. PubMed ID: 1846038
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Studies on new attenuated strains of type III live poliomyelitis vaccine. I. Development of a new type III attenuated poliovirus.
    Chin Med J (Engl); 1980 Sep; 93(9):583-90. PubMed ID: 6253236
    [No Abstract]   [Full Text] [Related]  

  • 32. Attenuation and reversion of the Sabin vaccine strains of poliovirus.
    Minor PD
    Dev Biol Stand; 1993; 78():17-26. PubMed ID: 8388828
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Poliovirus attenuation and pathogenesis in a transgenic mouse model for poliomyelitis.
    Racaniello VR; Ren R; Bouchard M
    Dev Biol Stand; 1993; 78():109-16. PubMed ID: 8388820
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Live attenuated oral poliovirus vaccine.
    Melnick JL
    Rev Infect Dis; 1984; 6 Suppl 2():S323-7. PubMed ID: 6330836
    [TBL] [Abstract][Full Text] [Related]  

  • 35. INTRATYPIC SERODIFFERENTIATION TESTS ON POLIO TYPE 1 VIRUS STRAINS ISOLATED BEFORE AND AFTER VACCINATION WITH ATTENUATED SABIN TYPE 1 POLIO VACCINE.
    HAHNEMANN F; SIBONI K; GODTFREDSEN A
    Acta Pathol Microbiol Scand; 1964; 61():437-45. PubMed ID: 14164891
    [No Abstract]   [Full Text] [Related]  

  • 36. Rational design of genetically stable, live-attenuated poliovirus vaccines of all three serotypes: relevance to poliomyelitis eradication.
    Macadam AJ; Ferguson G; Stone DM; Meredith J; Knowlson S; Auda G; Almond JW; Minor PD
    J Virol; 2006 Sep; 80(17):8653-63. PubMed ID: 16912313
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ethical and safety considerations for the use in clinical trials of new attenuated poliovirus strains.
    Horaud F
    Dev Biol Stand; 1993; 78():149-54; discussion 154-5. PubMed ID: 8388825
    [No Abstract]   [Full Text] [Related]  

  • 38. Limited in vivo susceptibility of the South American monkey -Cebus apella- to type 1 poliovirus: physical and histopathological observations after intraspinal inoculation.
    Abe S; Doi Y; Marchevsky RS; Leal MD; Homma A
    Biken J; 1985 Jun; 28(1-2):21-30. PubMed ID: 3000348
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Oral poliomyelitis vaccination: why should transmission of vaccine viruses to unvaccinated infants be avoided if possible?].
    Wiersbitzky S
    Kinderarztl Prax; 1993 May; 61(3):120-1. PubMed ID: 8392122
    [No Abstract]   [Full Text] [Related]  

  • 40. Prevalence of vaccine-derived polioviruses in stools of immunodeficient children in South Africa.
    Pavlov DN; Van Zyl WB; Van Heerden J; Kruger M; Blignaut L; Grabow WO; Ehlers MM
    J Appl Microbiol; 2006 Dec; 101(6):1367-79. PubMed ID: 17105568
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.